Weight loss injections

approved for the treatment of type 2 diabetes. In diabetic patients, treatment with semaglutide (Ozempic) has been shown to improve blood glucose levels. In addition, patients experience weight loss of 10-20% of body weight. Semaglutide (Ozempic) is administered as weekly subcutaneous injections, as compared to Semaglutide (Rybelsus) which is taken orally in tablet form once a day. Semaglutide (WeGovy) has received approval for treatment of obesity. Due to high demand there is a worldwide shortage of these medications.